Someone Is Trying to Discredit the Story of Peter Thiel's Interest in Young Blood - 2017-06-16
When Inc. magazine's Jeff Bercovici reported last August that billionaire Trump-supporter Peter Thiel had repeatedly expressed interest in the idea of harvesting the blood of young people to maintain his own youth, it left an indelible mark on Thiel's public persona, as captured by headlines like "Peter Thiel Wants to Inject Himself with Young People's Blood" and "Here's Why Peter Thiel May Be Interested In Younger People's Blood." The television show Silicon Valley eventually featured a tech mogul who hires a young "transfusion associate" to provide him with fresh blood on-demand.
Thiel's ultra-libertarian politics and history of supporting vaguely nefarious projects—such as his successful plot to kill Gawker, his controversial application for New Zealand citizenship, and his recent suggestion that political corruption could be a good thing—have earned him the aura of a Silicon Valley fiend. His interest in Ambrosia, an obscure startup that injects older customers with blood drawn from youthful donors, was the perfect detail to round out his villainy.
So it came as a shock Wednesday when TechCrunch reporter Sarah Buhr published an article that claimed the story about Thiel's blood interest was untrue. Bercovici had reported that Ambrosia founder Jesse Karmazin told him that Jason Camm, the "chief medical officer" for Thiel Capital, approached Karmazin in July 2016 to express interest in Ambrosia. That reporting, Buhr wrote, was false: "According to Karmazin…he was never contacted by Thiel or anyone associated with Thiel Capital."